key: cord-1008222-8oowst52
authors: de Freitas, Raquel Falcão; Torres, Sofia Cardoso; Martín-Sánchez, Francisco Javier; Carbó, Adrián Valls; Lauria, Giuseppe; Nunes, José Pedro L.
title: Syncope and COVID-19 disease – A systematic review
date: 2021-08-27
journal: Auton Neurosci
DOI: 10.1016/j.autneu.2021.102872
sha: 8103492a0b3e4fcfb03946c6573ccbf42709afd8
doc_id: 1008222
cord_uid: 8oowst52

Background Syncope is not a common manifestation of COVID-19, but it may occur in this context and it can be the presenting symptom in some cases. Different mechanisms may explain the pathophysiology behind COVID-19 related syncope. In this report, we aimed to examine the current frequency and etiology of syncope in COVID-19. Methods A systematic review across PubMed, ISI Web of Knowledge and SCOPUS was performed, according to PRISMA guidelines, in order to identify all relevant articles regarding both COVID-19 and syncope. Results We identified 136 publications, of which 99 were excluded. The frequency of syncope and pre-syncope across the selected studies was 4.2% (604/14,437). Unexplained syncope was the most common type (87.9% of the episodes), followed by reflex syncope (7.8% of the cases). Orthostatic hypotension was responsible for 2.2% of the cases and syncope of presumable cardiac cause also accounted for 2.2% of cases. Arterial hypertension was present in 52.0% of syncope patients. Neither the use of angiotensin receptor blockers nor angiotensin converting enzyme inhibitors were associated with an increased incidence of syncope (chi-square test 1.07, p 0.30), unlike the use of beta-blockers (chi-square test 12.48, p < 0.01). Conclusion Syncope, although not considered a typical symptom of the COVID-19, can be associated with it, particularly in early stages. Different causes of syncope were seen in this context. A reevaluation of blood pressure in patients with COVID-19 is suggested, including reassessment of antihypertensive therapy, especially in the case of beta-blockers.

The ongoing Coronavirus pandemic has proved to be a challenging setback to the health of the world population ever since its first cases were announced in the city of Wuhan, China, around December, 2019. As of the 1st of July 2021, there have been a total of approximately 181 million confirmed cases of COVID-19 (Coronavirus disease 2019) worldwide and 3.9 million deaths, translating to a fatality rate of 2%. (1) SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a novel betacoronavirus and COVID-19 is the infectious disease caused by this novel virus. Its spike protein (glycoprotein S) determines the specificity of the virus for epithelial cells of the respiratory tract.

(2) It is composed of a receptor binding domain that recognizes the ACE-2 (type 2 angiotensin converting enzyme) receptor specifically, allowing the entrance of the virus into its target cells.

(3) The ACE-2 receptor can be found on the surface of epithelial cells in the lungs, intestines, kidneys and blood vessels. (2) It is currently known that, although the novel SARS-CoV-2 virus can lead to significant disease in the respiratory system, it can also negatively affect several other vital organ systems. Significant damage, namely, to the cardiovascular, nervous and hematopoietic systems has been outlined and an impact in hemostasis has also been thoroughly discussed as blood hypercoagulability is common among hospitalized COVID -19 signs and symptoms such as pallor, sweating, nausea, palpitations) without being followed by a loss of consciousness. (8) In the light of a severe systemic disease, non-traumatic transient loss of consciousness can have distinct etiologies, varying from the benign reflex syncope and syncope due to orthostatic hypotension to the increasingly serious cardiac syncope. (9) Apart from unexplained syncope, these three main groups stem from different mechanisms and, therefore, may require specialized treatment. Consequently, an accurate diagnosis becomes imperative.

Recently, some case reports and case-series have emerged reporting syncope as a possible symptom of COVID-19, whether it had developed at the onset or during the course of the disease. (6) It is important to mention that some of these reports outline its occurrence days before the main respiratory symptoms, or even as an isolated phenomenon. (10) If a valid relationship between COVID-19 and syncope is established, a number of patients could be isolated in a timely manner, minimizing the contagious phase.

In the present report, we aimed to systematically review the recent published literature that describes syncope or presyncope as a symptom of COVID-19, having it been observed in the days before or after the diagnosis. We aimed to calculate its frequency and divide it into each different type of syncope observed.

As a secondary aim of the review, the investigation of the relationship between syncope and use of angiotensin receptor inhibitor drugs (ACEi), angiotensin receptor blockers (ARBs) and/or beta-blockers in the context of COVID-19 was carried out. This seemed to be important to investigate since arterial hypertension is a common comorbidity among COVID-19 patients (11) , and the use of standard anti-hypertensive agents could influence the incidence of this symptom.

J o u r n a l P r e -p r o o f Journal Pre-proof METHODS 

Regarding our population of interest, we were in the search for studies that simultaneously described COVID-19 and syncope or presyncope presented as a possible symptom of the acute infection or occuring in a post-acute COVID-19 setting. Articles were excluded if they described falls in the context of COVID-19 that were not stated to be of syncopal origin; episodes of syncope not temporally related with SARS-CoV-2 infection (for example, occurring throughout the year prior to the infection) and episodes of syncope with another possible underlying cause mentioned in the study as relevant apart from COVID-19. We included case-series, case-reports, cross-sectional studies with prospective data collection, retrospective analyses and letters published in 2020 or 2021 for which it was possible to extract an exact number of patients with COVID-19 exhibiting syncope/presyncope. We did not restrict articles to witnessed syncope nor exclude articles that did not describe the specific comorbidities, clinical characteristics or evolution exhibited by the pre/syncope cohort. This because our primary outcome measure was to quantify the number of COVID-19 related pre/syncopal episodes published in the literature thus far.

We considered articles written in English, Spanish, French, Italian, or Portuguese. Articles written in German, Hungarian or Mandarin were excluded. (since the authors are not familiar with these languages).

A comprehensive literature search was carried out with the purpose of identifying all reported articles relating syncope to COVID-19, according to the guidelines for Preferred Reporting

The search query, which took place on the 9 th of March 2021, included the following MeSH terms and keywords: "("COVID-19" OR "COVID 19" OR "SARS-COV-2" OR "coronavirus" OR "2019 novel coronavirus") AND ("syncope" OR "presyncope" OR "syncopal"). Additionally, we scanned the list of references from the included studies in this analysis and of systematic reviews pertaining to neurological symptoms in the context of COVID-19.

Two investigators independently assessed whether the studies addressed the topic in question and if all the inclusion/exclusion criteria were met. Initially, this was done according to the "screening phase", where only the title and the abstract were analyzed. After this process, 52 articles were considered eligible. This was followed by the "inclusion phase", where the integral text was fully evaluated. Any doubtful situation was solved by consensus between the authors, after which, concerning study eligibility, 100% agreement between authors was seen in each step of the study assessment.

From the selected articles, two authors worked independently to retrieve the following data: location, number of patients (with and without pre/syncope), age, sex and ethnicity when available, comorbidities (from patients with and without pre/syncope), chronic medications the patients were on regarding treatment of arterial hypertension and the description of the clinical course, including relevant laboratory findings and any auxiliary exams performed, such as computerized tomography scans and cardiac magnetic resonances. Any doubtful situation was solved by consensus between the authors.

Quality of the observational cohorts and cross-sectional studies and case-series was evaluated using the National Heart, Lung and Blood Institute study quality assessment tools (13) and is

With the use of our keywords, we obtained 51 results from Medline (PUBMED), 28 from ISI Web of Knowledge and 50 from SCOPUS (Figure 1 ), 7 from scanning the references of the selected articles and adequate systematic reviews and -with a total number of 37 articles selected for the purpose of the present study ( Figure 1 ). The complete set of selected studies is presented in Table 3 . SARS-CoV-2 infection was diagnosed by real-time reverse transcriptase polymerase chain reaction (RT-PCR) or a chest X-ray or CT scan showing the characteristic bilateral interstitial pneumonia of COVID-19 in all cases, except in the report by Romero-Sánchez et al., in which a minority of patients were diagnosed by means of serological testing. (14) The excluded full-text articles are presented in Table 4 , with the corresponding reasons.

Of the 37 included articles, 18 were case reports (15) The sample size included in the studies varied from 1 to 5427 patients. The mean age ranged from 26 to 84 years of age. Considering the studies in which it was possible to extract the sex of COVID-19 patients who experienced syncope, we found that 61.2% were male. The overall J o u r n a l P r e -p r o o f Journal Pre-proof male percentage (including COVID-19 patients with syncope and without syncope) was 55.9%.

Ethnicity data, when available, are presented in Table 3 .

Information regarding number of participants, mean age, sex and usage of ARBs/ACEi as well as usage of beta-blockers in the syncope versus non-syncope cohort was available for 5 studies and is presented in Table 5 .

There were 604 cases of syncope and pre-syncope related to COVID-19 out of a total of 14,438 patients contemplated in this review, comprising an overall frequency of 4.2%.

The majority of studies, 16 Two studies (31) (32) described the occurrence of syncope in COVID-19 survivors, 3 to 4 weeks after diagnosis, in a post-acute COVID-19 phase. This raises the possibility of syncope playing a role not only during the acute phase of the disease, but also as a long-term consequence. In both these cases, the patients were diagnosed with a Postural Orthostatic Tachycardia Syndrome, included in the autonomic dysfunctions.

As stated before, unexplained pre/syncope was the most common cause of the transient loss of consciousness, being 87.9% (531/604) of the reported episodes. The overall frequency of reflex pre/syncope was 7.8% (47/604). Orthostatic hypotension accounted for 2.2% (13/604) and presumable cardiac pre/syncope was responsible for 2.2% (13/604) of the cases as well. The most common laboratory findings in COVID-19 patients presenting with syncope included elevated C-reactive protein, elevated D-dimer and elevated troponin. However, the elevation of C-reactive protein and D-dimer was more frequently observed than the elevation of troponin.

From the studies that discriminated laboratory data on admission, we found that the elevation of D-dimer and C-reactive protein was present in 32% of the patients that presented with COVID-19 and syncope. ( (48) Most of the reports included in our review included patients with a mean age of 60 years of age or older, with a few exceptions lying in the 40-60 age group (Table 3 ). This suggests that syncope, as a symptom of COVID-19, is more frequent in an elderly population. Because this population is particularly vulnerable to this novel virus, special attention should be paid.

Considering the post-acute COVID-19 scenario, two recurring pre-syncopal episodes were described, and these happened in 26 and 36 year olds (31) (32), which offers a great contrast to the age of people who suffered from syncope during the active infection. Long-term COVID-19 sequelae are still in need of further investigation in order to grasp the future impact that the infection might have on its survivors, especially after a longer period of time.

Arterial hypertension was present in more than half of the patients with COVID-19 and syncope for whom detailed data were available (Table 6 ). We did not find a significant association between the use of either ACEi or ARBs and the occurrence of syncope. Concerning the use of beta blockers, a significant difference was observed, with syncope being more frequent in patients taking this type of drugs. This may indicate that an adequate compensatory response of the heart rate is important in this inflammatory setting. The present results suggest a careful reevaluation of blood pressure whenever a hypertensive patient develops COVID-19, especially if beta-blockers are used.

The presence of lower heart rate and lower blood pressure at admission that was observed in patients presenting with syncope did not necessarily correlate with severe COVID-19, as it was noted that these patients required less intensive care than the non-syncope cohort. (6) Patients with self reported syncope had lower in-hospital mortality than those without this symptom, in the report by Chou et al. (48) (and also in our results). This may not represent the situation concerning the whole universe of COVID-19 patients, but may be due to the fact that patients with alternative and serious neurological conditions were represented heavily in the control group. One may speculate that syncope was drug-associated in some cases, and that therefore, by having a reversible nature, may also contribute to this finding. Different authors suggested several types of dysfunction of the cardiovascular system, of the neurological system, or of both, in the context under evaluation. ACE2 is believed to be involved in the regulation of cardiovascular function at the central nervous system level. (49) Perhaps the affinity of SARS-Cov-2 to the ACE-2 receptors could play a role in affecting the baroreflex response. (36) Following this reasoning, the inappropriate baroreflex response could lead to a partial inhibition of the compensatory increase of heart rate during fever and acute

hypoxemia. An inadequate response of heart rate was suggested in some cases, (10) (36) a situation perhaps worsened in the context of beta-blocker use.

In the present review, elevated D-dimers were one of the most frequent abnormal laboratory findings (32%), supporting the concept that blood hypercoagulability, which is common amongst COVID-19 patients, is also present in patients who experience syncope while infected with SARS-CoV-2. A rise in troponins was also noted across some studies, underlining the impact of the virus in provoking a cardio-inflammatory response. (50) Limitations of this systematic review

The large majority of studies in the present review are case reports, hence, the limitations include those intrinsic to this kind of studies, including the inability to generalize the results, mainly due to the fact that these studies do not show a representative population. In addition, case reports and case series have a retrospective nature, which means they sometimes lack relevant information. For example, some case reports did not mention the chronic medications the patients were on, although they described the respective comorbidities.

The population sample size is 14,437 which, when compared to the millions of COVID-19 cases worldwide, may be the subject of selection bias. We also analyzed a substantial amount of retrospective studies, most of which were not primarily designed to assess the frequency of syncope in the context of COVID-19 and therefore provide insufficient information regarding the syncope cohort. Given the nature of this topic, the number of published studies focusing on comparing syncope cohorts with non-syncope cohorts in a COVID-19 setting is still limited, hindering the ability to reach certain conclusions. We attempted at making a distinction between the different types of syncope, however, in some studies, we found it impossible to do so. Furthermore, our inclusion criteria limited the articles to those written in the English, Spanish, French, Italian and Portuguese languages, which may have omitted significant studies.

Conclusions Syncope is a relatively uncommon manifestation of COVID-19, with an overall frequency of 4.2% in the reports under analysis. Different types of mechanisms leading to syncope in this context were observed, including reflex syncope, orthostatic hypotension and cardiac syncope.

Syncope may be the presenting symptom of COVID-19 and its adequate recognition as such might be useful in allowing for an earlier diagnosis. The presence of this symptom does not necessarily correlate with severe COVID-19 and may be associated to lower in-hospital mortality. Arterial hypertension was particularly prevalent in patients with COVID-19 and syncope, which may indicate that maintaining the usual antihypertensive medication may be inadequate in some cases of COVID-19. This is particularly important in the case of beta-blockers use, drugs that were shown to be associated with an increased incidence of syncope. Further studies may be of interest in order to further evaluate the frequency, etiology and impact of syncope in this type of patients. 

Was the study populatio n clearly specified and defined? Syncope was the least common symptom, with an incidence of 152 of 3054 (5%) in the all COVID-19 cohort. 8% of the >80 age group suffered from an episode of syncope, being the age group with the biggest incidence of syncope. 5% of the patients who had an episode of syncope died, whereas in the non-syncope group, 14% of patients died. Table 3 . Summary of included articles. Pts -patients; ARBs -angiotensin receptor blockers; PPMpermanent pacemaker implantation; ECG -electrocardiogram; ICD -implantable cardioverter-defibrillator; AV -atrioventricular; ACE-I -angiotensin-converting-enzyme inhibitors; CMR -cardiac magnetic resonance; CSF -cerebrospinal fluid; CT -computed tomography; MRImagnetic resonance imaging; RT-PCR -real time polymerase chain reaction;

CRP -C-Reactive Protein, NT-proBNP -N-terminal type B natriuretic peptide; POTS -Postural Orthostatic Tachycardia Syndrome; BP -blood pressure. For references see text.

J o u r n a l P r e -p r o o f 

WHO Coronavirus (COVID-19) Dashboard 2021

The human coronaviruses (HCoVs) and the molecular mechanisms of SARS-CoV-2 infection

SARS-CoV-2: structure, biology, and structure-based therapeutics development. Frontiers in cellular and infection microbiology

Hematological findings and complications of COVID-19. American journal of hematology

Cardiac manifestations in COVID-19 patients-A systematic review

Syncope and presyncope in patients with COVID-19. Pacing and Clinical Electrophysiology

Neurological manifestations of COVID-19: a systematic review and meta-analysis of proportions

ESC guidelines for the diagnosis and management of syncope

ESC Guidelines for the diagnosis and management of syncope

Syncope as the presenting symptom of COVID-19 infection. HeartRhythm case reports

COVID-19 and arterial hypertension: Hypothesis or evidence?

Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement

Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry

COVID-19 in a patient presenting with syncope and a normal chest X-ray

Massive pulmonary embolism in a COVID-19 patient: a case report

Brugada syndrome, and COVID-19 lung disease

Diffuse Myocardial Inflammation in COVID-19 Associated Myocarditis Detected by Multiparametric Cardiac Magnetic Resonance Imaging

Non-epileptic seizures in autonomic dysfunction as the initial symptom of COVID-19

COVID-19 infection unmasking Brugada syndrome

An Atypical Presentation of Novel Coronavirus Disease 2019 (COVID-19). The American Journal of Medicine

A Case of COVID-19 Encephalitis. Brain, Behavior, and Immunity

COVID-19-Induced Diabetic Ketoacidosis in an Adult with Latent Autoimmune Diabetes

A Giant Right-Heart Thrombus-in-Transit in a Patient with COVID-19 Pneumonia

ECG: essential in care of patients with COVID-19

Global Prevalence of Neurological Manifestations Among Patients Hospitalized with COVID-19: A Report of the Global Consortium Study of Neurologic Dysfunction in COVID-19 (GCS-NeuroCOVID) and the European Academy of Neurology

Angiotensin-converting enzyme 2: central regulator for cardiovascular function

Clinical utility of cardiac troponin measurement in COVID-19 infection